Please assess the completion status of the following clinical trial:

Trial Title: Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Enteric hyperoxaluria (\>0.5 mM/day; \> 45 mg/day) due to fat malabsorption from inflammatory bowel disease (Crohn's Disease). (Patients in remission maintained on stable doses of Remicade/Imuran/Methotrexate every 8 weeks can be recruited as long as the trial can be conducted between 5 and 8 weeks after the last dose); OR~* Enteric hyperoxaluria (\>0.5 mM/day; \> 45 mg/day) from gastric bypass procedures (gastric bypass for obesity, or other surgical causes of gastric dumping and fat malabsorption (e.g., antrectomy, vagotomy and pyloroplasty for gastric ulcers) (Patients with inflammatory bowel disease must be in clinical remission); OR~* Calcium oxalate nephrolithiasis and mild hyperoxaluria of unknown etiology (\>0.35 mM/day) (n=60)~* Presence of radioopaque stones on x-ray, or a history consistent with passage of a stone or stone surgery or extracorporeal shock wave lithotripsy (ESWL) in the last 5 years and if on stone medication, doses have remained stable for at least 3 months~* Stone composition confirmed either by stone analysis demonstrating composition equal to or more than 50% calcium oxalate, or by radiographic demonstration of a calcific renal stone in the presence of hyperoxaluria~Exclusion Criteria:~* On immunosuppressive medications (excluding small stable doses of prednisone of 10 mg or less)~* Human immunodeficiency virus (HIV) infection, known enteric bacterial infection, or history of splenectomy~* Have a current malignancy, other than superficial skin cancers that have been excised, unless they felt to be in complete remission (\> 5 years)~* Previous colectomy~* Have completed a course of oral or parenteral antibiotics less than 2 weeks before initiation of the study (patients who require a course of antibiotics during the period of preparation administration will be withdrawn from the study and excluded from the final analysis)~* Patient pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
- Oxadrop (Type: ACTIVE_COMPARATOR): Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
- Agri-King Synbiotic (Type: ACTIVE_COMPARATOR): Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae

Based on this trial design, predict the completion outcome and termination type (if applicable).